Literature DB >> 1909051

Antimicrobial susceptibility of Bacillus anthracis.

M Doğanay1, N Aydin.   

Abstract

22 Bacillus anthracis isolates were tested for susceptibility to 27 antimicrobial agents by agar dilution. All isolates were sensitive to penicillins and did not produce beta-lactamase. Although all isolates were sensitive to cefazolin, cephalothin, cephradine and cefoperazone 19 isolates were resistant to cefuroxime, 18 to cefotaxime, 18 to ceftizoxime, 9 to ceftriaxone and 21 to ceftazidime. All isolates were also found to be sensitive to other antimicrobials tested. The new antimicrobial agents, ofloxacin and ciprofloxacin showed very good activity with MICs of 0.03-0.06 mg/l.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1909051     DOI: 10.3109/00365549109024319

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  22 in total

1.  Biological Warfare: Implications for Antimicrobial Use.

Authors:  Ethan Rubinstein; Itzhak Levi
Journal:  Curr Infect Dis Rep       Date:  2002-02       Impact factor: 3.725

2.  Antibiotic susceptibilities of 96 isolates of Bacillus anthracis isolated in France between 1994 and 2000.

Authors:  Jean-Didier Cavallo; Francoise Ramisse; Monique Girardet; Josée Vaissaire; Michelle Mock; Eric Hernandez
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

3.  Efficacy of Daptomycin against Bacillus anthracis in a murine model of anthrax spore inhalation.

Authors:  Henry S Heine; Jennifer Bassett; Lynda Miller; Bret K Purcell; W Russell Byrne
Journal:  Antimicrob Agents Chemother       Date:  2010-07-19       Impact factor: 5.191

4.  Beta-lactamase gene expression in a penicillin-resistant Bacillus anthracis strain.

Authors:  Yahua Chen; Fred C Tenover; Theresa M Koehler
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

5.  Provider and health care system response to a bioterrorist attack.

Authors:  J D Malone
Journal:  Proc (Bayl Univ Med Cent)       Date:  2001-07

6.  X-ray structure of the ternary MTX.NADPH complex of the anthrax dihydrofolate reductase: a pharmacophore for dual-site inhibitor design.

Authors:  Brad C Bennett; Qun Wan; Md Faiz Ahmad; Paul Langan; Chris G Dealwis
Journal:  J Struct Biol       Date:  2009-05       Impact factor: 2.867

Review 7.  New developments in vaccines, inhibitors of anthrax toxins, and antibiotic therapeutics for Bacillus anthracis.

Authors:  J M Beierlein; A C Anderson
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

8.  Antimicrobial susceptibility testing of Bacillus anthracis: comparison of results obtained by using the National Committee for Clinical Laboratory Standards broth microdilution reference and Etest agar gradient diffusion methods.

Authors:  M Jasmine Mohammed; Chung K Marston; Tanja Popovic; Robbin S Weyant; Fred C Tenover
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

9.  MICs of selected antibiotics for Bacillus anthracis, Bacillus cereus, Bacillus thuringiensis, and Bacillus mycoides from a range of clinical and environmental sources as determined by the Etest.

Authors:  Peter C B Turnbull; Nicky M Sirianni; Carlos I LeBron; Marian N Samaan; Felicia N Sutton; Anatalio E Reyes; Leonard F Peruski
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

10.  Novel broad-spectrum bis-(imidazolinylindole) derivatives with potent antibacterial activities against antibiotic-resistant strains.

Authors:  Rekha G Panchal; Ricky L Ulrich; Douglas Lane; Michelle M Butler; Chad Houseweart; Timothy Opperman; John D Williams; Norton P Peet; Donald T Moir; Tam Nguyen; Rick Gussio; Terry Bowlin; Sina Bavari
Journal:  Antimicrob Agents Chemother       Date:  2009-07-27       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.